The role of CD40 and CD137 in immune responses to cancer : a study of monoclonal antibody mediated immunomodulation in two murine tumour models
The role of CD40 and CD137 in immune responses to cancer : a study of monoclonal antibody mediated immunomodulation in two murine tumour models
Specific monoclonal antibodies (mAb) against CD40 and CD137 were used to deliver a signal through the ligation and crosslinking of the surface receptor. The character of these responses and potential for immunotherapy were investigated in vitro and in vivo using two murine cancer models, CT26 and B16.
FACS analysis of CT26 and B16 demonstrated that neither expresses CD40 or CD137. Furthermore the mAb used, FGK45, 3/23 (CD40) and Lob 12 (CD137), had no effect on tumour growth in vitro.
CT26-bearing BALB/c and B16-bearing C57B16 mice were treated with anti-CD40 mAb. Growth of established subcutaneous (sc) and intradermal (id) CT26 was significantly reduced. In contrast there was no protection from pulmonary CT26. Pulmonary B16 deposits were significantly reduced with anti-CD40 mAb.
The pulmonary CD8+ lymphocyte population increased in response to anti-CD40 mAb. In BALB/c mice this was partly tumour dependent, but tumour independent in C57B16 mice. The CD19+ population also expanded but the CD4+ cell number was unaffected by anti-CD40 mAb.
The response to anti-CD40 mAb was found to involve IFN-γ, but this cytokine alone had no in vivo effect on the growth of CT26, suggesting that anti-CD40 mAb was not effective merely through increased levels of IFN-γ.
Selective depletion of CD4+ and CD8+ cells demonstrated that tumour abrogation with anti-CD40 mAb was dependent on CD8+ cells, but did not require CD4+ cells. The specific effector cells could not be isolated in vitro.
Transfection of CD40 ligand into CT26 cells gave greatly enhanced protection against tumour growth compared with anti-CD40 mAb.
Immunomudulation through CD40 and CD137 can result in a powerful and enduring response to tumour antigen that may be useful in the development of novel strategies in cancer immunotherapy.
University of Southampton
Green, Michael
857b7cfd-a289-4143-9eb0-90434825a47d
2003
Green, Michael
857b7cfd-a289-4143-9eb0-90434825a47d
Green, Michael
(2003)
The role of CD40 and CD137 in immune responses to cancer : a study of monoclonal antibody mediated immunomodulation in two murine tumour models.
University of Southampton, Doctoral Thesis.
Record type:
Thesis
(Doctoral)
Abstract
Specific monoclonal antibodies (mAb) against CD40 and CD137 were used to deliver a signal through the ligation and crosslinking of the surface receptor. The character of these responses and potential for immunotherapy were investigated in vitro and in vivo using two murine cancer models, CT26 and B16.
FACS analysis of CT26 and B16 demonstrated that neither expresses CD40 or CD137. Furthermore the mAb used, FGK45, 3/23 (CD40) and Lob 12 (CD137), had no effect on tumour growth in vitro.
CT26-bearing BALB/c and B16-bearing C57B16 mice were treated with anti-CD40 mAb. Growth of established subcutaneous (sc) and intradermal (id) CT26 was significantly reduced. In contrast there was no protection from pulmonary CT26. Pulmonary B16 deposits were significantly reduced with anti-CD40 mAb.
The pulmonary CD8+ lymphocyte population increased in response to anti-CD40 mAb. In BALB/c mice this was partly tumour dependent, but tumour independent in C57B16 mice. The CD19+ population also expanded but the CD4+ cell number was unaffected by anti-CD40 mAb.
The response to anti-CD40 mAb was found to involve IFN-γ, but this cytokine alone had no in vivo effect on the growth of CT26, suggesting that anti-CD40 mAb was not effective merely through increased levels of IFN-γ.
Selective depletion of CD4+ and CD8+ cells demonstrated that tumour abrogation with anti-CD40 mAb was dependent on CD8+ cells, but did not require CD4+ cells. The specific effector cells could not be isolated in vitro.
Transfection of CD40 ligand into CT26 cells gave greatly enhanced protection against tumour growth compared with anti-CD40 mAb.
Immunomudulation through CD40 and CD137 can result in a powerful and enduring response to tumour antigen that may be useful in the development of novel strategies in cancer immunotherapy.
Text
1230578.pdf
- Version of Record
More information
Published date: 2003
Identifiers
Local EPrints ID: 466608
URI: http://eprints.soton.ac.uk/id/eprint/466608
PURE UUID: e5757bd2-67e2-4213-a17c-be1a9f6916c2
Catalogue record
Date deposited: 05 Jul 2022 06:01
Last modified: 16 Mar 2024 20:48
Export record
Contributors
Author:
Michael Green
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics